Otis W. Brawley's most recent trade in PDS Biotechnology Corporation was a trade of 22,700 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 22,700 | 22,700 | - | - | Employee Stock Option (Right to Buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,216 | 9,216 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 2,518 | 11,252 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Otis W. Brawley | Director | Purchase of securities on an exchange or from another person at price $ 0.56 per share. | 31 Mar 2025 | 35,640 | 35,640 | - | 0.6 | 19,958 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 121.18 per share. | 14 Mar 2025 | 1,819 | 9,929 (0%) | 0% | 121.2 | 220,426 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 121.18 per share. | 14 Mar 2025 | 812 | 10,741 (0%) | 0% | 121.2 | 98,398 | Common Stock |
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Lyell Immunopharma Inc | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 8,734 (0%) | 0% | 0 | Common Stock | |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 147.48 per share. | 15 Mar 2024 | 1,678 | 7,305 (0%) | 0% | 147.5 | 247,471 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 147.48 per share. | 15 Mar 2024 | 750 | 8,055 (0%) | 0% | 147.5 | 110,610 | Common Stock |
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 5,904 (0%) | 0% | 0 | Common Stock | |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 16 Mar 2023 | 1,658 | 4,844 (0%) | 0% | 136.8 | 226,848 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 16 Mar 2023 | 741 | 5,585 (0%) | 0% | 136.8 | 101,384 | Common Stock |
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Lyell Immunopharma Inc | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 3,399 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 17 Mar 2022 | 1,785 | 2,368 (0%) | 0% | 136.8 | 244,224 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 136.82 per share. | 17 Mar 2022 | 797 | 3,165 (0%) | 0% | 136.8 | 109,046 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 162.16 per share. | 18 Nov 2021 | 404 | 404 (0%) | 0% | 162.2 | 65,513 | Common Stock |
| Agilent Tech | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 162.16 per share. | 18 Nov 2021 | 179 | 583 (0%) | 0% | 162.2 | 29,027 | Common Stock |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Sep 2021 | 5,910 | 5,910 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Sep 2021 | 1,255 | 1,255 (0%) | 0% | 0 | Common Stock | |
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| PDS Biotechnology Corporation | Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) |